Blood loss and bleeding complications may often be observed in critically ill patients on renal replacement therapies (RRT). Here we investigate procedural (i.e. RRT-related) and non-procedural blood loss as well as transfusion requirements in regard to the chosen mode of dialysis (i.e. intermittent haemodialysis [IHD] versus continuous veno-venous haemofiltration [CVVH]). Two hundred and fifty-two patients (122 CVVH, 159 male; aged 61.5±13.9 years) with dialysis-dependent acute renal failure were analysed in a sub-analysis of the prospective randomised controlled clinical trial-CONVINT-comparing IHD and CVVH. Bleeding complications including severity of bleeding and RRT-related blood loss were assessed. We observed that 3.6% of patients died related to severe bleeding episodes (between group P=0.94). Major all-cause bleeding complications were observed in 23% IHD versus 26% of CVVH group patients (P=0.95). Under CVVH, the rate of RRT-related blood loss events (57.4% versus 30.4%, P=0.01) and mean total blood volume lost was increased (222.3±291.9 versus 112.5±222.7 ml per patient, P <0.001). Overall, transfusion rates did not differ between the study groups. In patients with sepsis, transfusion rates of all blood products were significantly higher when compared to cardiogenic shock (all P <0.01) or other conditions. In conclusion, procedural and non-procedural blood loss may often be observed in critically ill patients on RRT. In CVVH-treated patients, procedural blood loss was increased but overall transfusion rates remained unchanged. Our data show that IHD and CVVH may be regarded as equivalent approaches in critically ill patients with dialysis-dependent acute renal failure in this regard.
Acute renal failure (ARF) is frequently observed in critically ill patients admitted to ICUs and constitutes an independent risk factor for death [1] [2] [3] [4] . Two major renal replacement therapy (RRT) strategies, i.e. intermittent haemodialysis (IHD) and continuous veno-venous hemofiltration (CVVH), are considered equivalent choices in dialysis-dependent ARF [5] [6] [7] [8] [9] [10] [11] [12] [13] . In a prospective randomised controlled trial (Continuous versus Intermittent RRT on the outcome of critically ill patients with ARF trial [CONVINT]), we recently compared IHD and CVVH and observed no statistically significant differences in regard to mortality, renal-related outcome measures, or survival at 14 days following RRT 5 .
Critically ill patients with ARF have an increased risk of blood loss and bleeding for numerous reasons, including need for anticoagulation and effects related to uraemic thrombopathy [1] [2] [3] 14 . The pathogenesis of uraemia-induced bleeding seems multifactorial 15, 16 . Abnormal plateletplatelet and platelet-vessel wall interaction may be regarded as a risk factor. Additional factors for bleeding may include the presence of infection and/or disseminated intravascular coagulation, recent trauma, post-surgical states, or gastrointestinal ulcers. On the other hand, despite decreased platelet counts or acquired platelet dysfunction, abnormalities within the coagulatory cascade, including activated fibrinolysis, may often be observed. Overall, ICU patients often show signs of a hypercoagulable state. This may increase the risk for respective cardiovascular and thromboembolic complications in this clinical setting [1] [2] [3] 14 .
When indicated, RRT may improve uraemia-induced platelet abnormalities but may also increase the risk of haemorrhage. This seems due to numerous facts including necessity of large-bore vascular access for RRT, interaction of blood with artificial surfaces of respective RRT devices, and use of anticoagulation to prevent clotting of the extracorporeal RRT circuit 2 . Systemic use of unfractionated or low molecular weight heparin, or regional anticoagulation using citrate represent routinely used strategies to avoid filter clotting [17] [18] [19] [20] . The clinical pros and cons of respective anticoagulation strategies are widely debated and respective treatment protocols may vary [18] [19] [20] [21] [22] [23] . From a clinical perspective, unfractionated heparin seems feasible to manage and monitor 1, 24 . Nevertheless, heparin may be contraindicated in patients with an increased risk for bleeding and in type II heparin-induced thrombocytopenia. Thus, some authors prefer regional citrate anticoagulation over heparin during continuous filtration as data indicate that regional anticoagulation may prolong filter running times [18] [19] [20] [21] [25] [26] [27] .
Previous data indicate that bleeding complications in critically ill patients with ARF increase overall morbidity and respective mortality rates. Interestingly, to the best of our knowledge, prospective comparative data from randomised controlled trials on blood loss, bleeding complications or transfusion requirements in regard to major dialysis modalities are currently unavailable. In the present subanalysis of a randomised controlled trial comparing IHD and CVVH 5 , we investigated the effect of dialysis modality on blood loss, bleeding complications, and respective transfusion requirements in critically ill patients with dialysis-dependent ARF. As the CONVINT trial was performed in the era prior to regional citrate anticoagulation, patients in both study arms received comparable doses of unfractionated heparin to perform RRT.
Methods

Design, study patients and inclusion/exclusion criteria
The analysis presented here is a sub-investigation of a prospective randomised controlled clinical trial 5 investigating effects of continuous versus intermittent RRT on the outcome of critically ill patients with dialysis-dependent acute renal failure. In brief, patients with ARF requiring RRT were included in a single-centre prospective randomised controlled openlabel trial (CONVINT) 5 . Need for RRT was defined as follows: (a) clinical presence of uraemia; (b) oliguria or anuria despite adequate fluid management; (c) fluid overload unresponsive to diuretics; (d) blood urea nitrogen levels >100 mg/l or a creatinine clearance <0.1 ml/kg of body weight/minute; (e) metabolic acidosis (i.e. pH <7.2) unresponsive to conventional treatment; or (f) hyperkalaemia unresponsive to conservative treatment. The following exclusion criteria applied: (a) advanced pre-existing chronic renal failure (i.e. serum creatinine >3 mg/dl or need for dialysis); (b) kidney transplant recipients; (c) ICU treatment not indicated; (d) denial of written informed consent. The study was approved by the local Ethics Committee and was designed in adherence with the Declaration of Helsinki and was registered at clinicaltrials.gov: NCT01228123 5 .
Patients were randomised to respective study groups (Group 1: IHD; Group 2: CVVH) at Study Day 0 (i.e. the day of randomisation). IHD was performed using polysulfone synthetic membranes. Standard treatment dose was daily IHD (four hours, bloodflow 200 to 250 ml/minute, bicarbonate buffered). Postdilutional CVVH was applied (24 hours daily, polysulfone synthetic membrane, bloodflow 200 ml/minute, prescribed filtration rates 35 ml per kg of body weight per hour, bicarbonate-buffered substitution fluids). For reasons of safety, subjects of both study groups were allowed to be switched to the respective other RRT modality in cases of significant medical reasons. Heparin was used as the preferred anticoagulant. Heparin doses were prescribed by the physician in charge without interference by the research team 5 .
Bleeding, associated complications and course of laboratory variables
Various definitions of 'major bleeding' have been used in previous trials. We defined bleeding complications in critically ill patients with RRT as the presence of one of the following criteria: (a) direct fatal bleeding and; (b) bleeding (severe) under RRT with a decrease in haemoglobin levels leading to transfusion of more than five units of packed red blood cells within seven days. We assumed that procedure-related blood loss is sufficiently balanced up to four units of packed red blood cells in seven days and that higher blood loss is based on non-procedural aetiology. RRT-related (i.e. procedure-related) blood loss was defined as blood loss in the extracorporeal system due to acute system clotting (extracorporeal system or membrane/filter) without the possibility of returning the respective patient's blood volume. The residual blood system volume was estimated at 200 ml.
The following indices were recorded: haemoglobin levels (Hb, given in g/l), platelet count (given in 10 9 /l), activated partial thromboplastin time (aPTT, given in seconds) and prothrombin time (given in percent). Number of transfused packed red blood cells (RBCs), fresh frozen plasma (FFP), and platelet concentrates (PC) were also recorded over the study interval. In order to compare RRT modalities in regard to haemoglobin levels, platelet counts and aPTT levels, a study period of seven days (beginning with the day of randomisation) was analysed. The number of transfused blood products, RBC (about 300 ml/pack), FFP (about 200 ml/pack) and PC (about 200 ml/ pack), was compared at seven days, 28 days and during the total trial. In a separate analysis, patients switched to the other respective RRT modality were also analysed. Assessment of laboratory indices was performed in a certified, accredited diagnostic laboratory of a tertiary care academic centre.
Presence of anaemia was recorded in the study population. Anaemia was defined as a haemoglobin concentration of below 120 g/l in women and below 135 g/l in men. Importantly, an 'absolute' transfusion threshold for critically ill patients has not been established so far. Here, haemoglobin levels of <80 g/l in critically ill patients were typically considered as a trigger for transfusion. FFP was typically given in cases of prolonged prothrombin times (i.e. Quick test <40%, corresponding to an International Normalized Ratio >1.8). All blood products were prescribed based on the clinical judgement of the attending physician without interference by the research team.
Statistical analyses
All data were checked for normal distribution (Kolmogorov-Smirnov test). For group comparisons, either unpaired t-tests or Mann-Whitney U tests were used, as appropriate. For categorical data, the chi-square test was used. To calculate group deviations in the course of respective study indices until day seven, day 28, or during the total trial, repeated measurement analysis of variance assessments were performed, if appropriate. For analysis of laboratory values during the first seven days, two-way analysis of variance was used, if appropriate. In cases of treatment modality switches, patients were investigated in the group that they were initially randomised to. Results are reported as median/ 25th to 75th percentile (quartile) ranges or means ± SDs, if not indicated otherwise. Significance was assigned when P <0.05. For statistical analysis MedCalc 12.0.1 Software was used (MedCalc Software, Mariakerke, Belgium).
Results
Characterisation of study patients and patients' demographics
Two hundred and fifty-two critically ill patients were investigated. Data from 128 patients (IHD group) and 122 patients (CVVH group) were analysed (missing data in two cases) 5 . At baseline, statistically significant differences were not noted between the study groups in regard to patient demographics, including gender, age, days in the ICU until study inclusion, disease severity (Acute Physiology and Chronic Health Evaluation [APACHE] II, Sequential Organ Failure Assessment [SOFA], Simplified Acute Physiology Score [SAPS]-2, and Therapeutic Intervention Scoring System [TISS]-28 scores), key physiological and haemodynamic indices and renal function (serum creatinine, serum urea, body weight or acid/base balance status) 5 . The main underlying condition for development of ARF was severe sepsis/septic shock (both groups >65% of study patients at baseline, P=0.89). No significant difference was observed between the investigated treatment modalities with regard to mortality, renal-related outcome measures, survival at 14 days, nor 30-day or all-cause intra-hospital mortality following RRT (IHD versus CVVH: 60.3 versus 54.6%, P=0.72) 5 .
The number of patients with advanced vascular disease, congestive heart failure, chronic obstructive pulmonary disease and metabolic disease did not differ between the two treatment arms. Moreover, days until dialysis, dialysis-free days, total fluid balance and mean daily ultrafiltration rates did not differ between the two study groups (all P >0.19). On day 21, serum creatinine levels, mean arterial pressures and the number of patients still on RRT also did not differ between the two treatment groups (P >0.1 for all comparisons) 5 .
Dialysis dose and anticoagulation strategies
In IHD-treated patients, the mean bloodflow rate was 222.9 ± 30.4 ml/minute, whereas the mean dialysate flow rate was 491.4 ± 6.2 ml/minute. The mean duration of IHD was 215.4 ± 82.3 minutes/session (i.e. about 3.6 hours). In the CVVH group, the mean applied RRT dose was 30.9 ± 7.0 ml/kilogram of body weight/hour (intended target dose was 35 ml per kilogram per hour). The mean bloodflow rate was 188.7 ± 29.4 ml/minute 5 . Anticoagulation requirements were monitored in both treatment arms as anticoagulation seemed important in regard to blood loss due to potential clotting of the extracorporeal system and transfusion requirements. Heparin was used in the majority of cases to prevent clotting of the extracorporeal circuit in both groups. Overall, anticoagulation was used in >70% of sessions (72.8% IHD group versus 74.4% CVVH group). Unfractionated heparin was used in 99.4% (IHD) versus 97.8% (CVVH) of RRT sessions, respectively 5 . Hirudine derivates or regional anticoagulation using citrate/calcium were used in the few remaining cases. Mean applied doses of continuously infused unfractionated heparin was higher in CVVH-treated patients (i.e. 782 ± 497 i.U./hour versus 683 ± 357 i.U./hour (IHD), P=0.0001) 5 . Between IHD sessions, the rate of continuously infused unfractionated heparin for prophylaxis of thromboembolism was reduced to 500 i.U./hour, if not indicated otherwise (e.g. in cases of atrial fibrillation). Heparin was stopped by the attending physician in cases of bleeding without interference by the research team.
Course of haemoglobin, platelet counts and activated partial thromboplastin time
At baseline (Table 1) , haemoglobin levels did not statistically differ between the two treatment groups. This also applied to baseline haematocrit levels (data not shown, P=0.72). At baseline, 109 (85%) patients in the IHD group and 101 (83%) patients in the CVVH group were initially diagnosed with anaemia. Over the initial seven-day trial interval, haemoglobin levels declined by 11.6% (IHD) and by 4.9% (CVVH group) in both treatment groups (Table 1) . Baseline platelet count also did not differ between the two study groups (P=0.06). A decrease of 7.2% (IHD) versus 11.6% (CVVH) in platelet count was noted until day three. This decline in platelet count was concordant between both study groups and was followed by a constant increase in platelet levels until the end of the initial seven-day interval (P <0.01). Overall, a 49.1% (IHD) versus a 30.9% (CVVH) increase was noted in platelet levels during the seven-day interval. aPTTs were prolonged in both study groups at baseline. In the initial seven-day interval, a significant aPTT decline and a (trend towards) normalisation was noted in both study groups (Table  1) .
Major bleeding episodes, bleeding complications and RRT-related blood loss
Major bleeding episodes, defined as transfusion of more than five packed RBCs within the first seven trial days occurred in 29 cases (23%) in the IHD group versus 32 cases (26%) in the CVVH group (P=0.95). In the subgroup of patients without a switch of RRT modality, no statistically significant between group-difference was noted (14% in IHD group versus 19% in CVVH group, P=0.65). In total, episodes of RRT-related blood loss were observed in 39 (30.4%) patients in the IHD group, and occurred in 70 (57.4%) CVVH-treated patients (P=0.01). The mean total estimated blood volume lost in patients randomised to receive IHD was 112.5 ± 222.7 ml versus 222.3 ± 291.9 ml in CVVHtreated individuals (means ± SD, P <0.001). Investigating the subgroup of patients with events of RRT-related blood loss, the mean total estimated blood loss per patient was 369.2 ± 261.7 ml (IHD) versus 384.3 ± 291.7 ml (CVVH), P=0.79 (means ± SD). In total, 206 events of RRT-related blood loss were noted. Procedure-related blood loss was investigated in patients who were switched to the respective other RRT modality also. In this subgroup, no statistically significant difference regarding procedural blood loss was noted between the two treatment groups. During the trial, nine out of 250 patients (i.e. 3.6%) died due to direct or indirect effects of severe bleeding episodes (five in IHD group, between group P=0.9). The main underlying disease in these non-survivors was sepsis (four in the IHD versus two in the CVVH group). Presence of disseminated intravascular coagulation was observed in these subjects. In two of these cases, severe gastrointestinal bleeding occurred; whereas another two patients died from haemorrhagic shock as a consequence of bleeding from oesophageal varices and underlying liver failure.
Transfusion requirements and impact of underlying disease
Statistically significant between-group differences were not observed in the number of transfused units of packed RBCs, FFP and PC over the total trial (Table 2) or the initial seven-day and 28-day interval (data not shown). After grouping of patients for respective underlying conditions (i.e. cardiogenic shock [20% of total population], severe sepsis/septic shock [68% of patients] and other conditions) significant between-group (IHD versus CVVH) differences were not observed regarding total packed RBC, total FFP or total PC requirements ( Table 2) , or in the initial sevenday and 28-day interval (data not shown). The respective underlying condition significantly influenced the number of transfused blood products in RRT treated individuals. Patients with severe sepsis/septic shock received significantly more mean total packed RBCs (P=0.003), total FFP units (P=0.001), and total PCs (P <0.0001) when compared to patients with cardiogenic shock (Figure 1 ).
Discussion
In this sub-investigation of a prospective randomised controlled trial investigating RRT modality-related effects in critically ill patients with dialysis-dependent ARF 5 , rates of bleeding episodes as well as procedural and non-procedural transfusion requirements were investigated. This was performed as data on bleeding episodes, severity of bleeding and transfusion requirements are currently restricted to observational reports in this specific population. Moreover controlled trials are unavailable so far. After analysis of data from 250 patients with dialysis-dependent ARF, we found that major all-cause bleeding complications were observed in 24% of study patients. In total, 206 events of RRT-related (i.e. procedural) blood loss were observed. Between-group differences in regard to fatal bleedings were not noted. In patients randomised to receive CVVH, the rate of RRT-related blood loss events and mean total estimated blood volume lost per patient was increased. Overall, transfusion rates did not depend on the chosen RRT modality but rather, on the underlying condition. From a clinical perspective, episodes of bleeding may often be observed in patients with established multiple organ failure and dialysis-dependent acute kidney injury. As stated before, this is further amplified by need for anticoagulation to prevent filter clotting. Nevertheless, CRRT anticoagulation strategies have changed over recent years. Whereas heparin was used as the standard anticoagulant in our trial, regional anticoagulation using citrate is now widely used in CRRT. This is performed as a citrate-based anticoagulation approach and may prolong filter running times and seems to reduce the overall risk of bleeding in respective patients [17] [18] [19] . Although the use of heparin in both study groups may be considered a limitation of our study, it may, on the other hand, best allow analysis of the effects induced by the respective RRT modality.
We observed that the overall need for transfusion of blood products was associated with the underlying condition. Severe infection as in severe sepsis/septic shock is well known to affect the coagulatory cascade, platelet numbers, and platelet function. We were therefore not surprised to observe that RRT-treated patients with severe sepsis/septic shock had significantly increased transfusion rates and rates of bleeding episodes when compared to patients with other underlying conditions (e.g. cardiogenic shock). Although the severity of sepsis-induced coagulopathy (e.g. disseminated intravascular coagulation) was not specifically assessed in our study population, it seems tempting to speculate that these effects might explain our observations. From a clinical perspective, we therefore conclude that the subpopulation of RRT-treated patients with severe sepsis/septic shock should be considered a high-risk population and should be monitored closely in this regard. Nevertheless, as severe sepsis and septic shock accounts for the major underlying reason for ARF in our study population, we cannot rule out an effect of sample size on our findings. Some limitations of our analysis demand discussion. First, various definitions of bleeding and different transfusion thresholds were previously proposed. For assessment of bleeding episodes and respective severity, we assumed that a decrease in haemoglobin levels leading to transfusion of more than five units of packed RBCs within seven days is to be considered relevant. Moreover, blood products were prescribed by the attending physician without interference by the research team. Although safety reasons and ethical considerations might impede study-related transfusion thresholds in this particular setting, this aspect may affect our data. Although our data might best reflect 'clinical reality' rather than 'artificial' trial conditions, we cannot rule out an overall effect of different transfusion thresholds. Second, the subanalysis of 'serious bleeding complications' only included the initial seven-day interval. This was performed as the number of study patients declined rapidly following this period due to high mortality rates of the cohort under investigation. Third, although unfractionated heparin was used in the majority of cases in both study groups, an effect of heparin dose cannot be ruled out. This seems due to the fact that unfractionated heparin was used continuously during CVVH and that individual heparin doses were again prescribed by the independent attending physician. Although RRT modality was deemed to have a little effect on the total dose of heparin, doses might have varied between patients (e.g. in cases of atrial fibrillation). Fourth, in regard to data on haemoglobin stability presented here, we cannot rule out an effect of varying ultrafiltration rates. As mean daily ultrafiltration rates did not differ between the study groups 5 , we believe that this may exert only minor effects on our analysis. Due to the nature of the underlying critical condition, patients were generally well hydrated at the beginning of their ICU stay. However, ICU patients tend to correct their hypervolaemic state over time, and the observed gradual decrease in haemoglobin levels might underestimate the true blood loss, given the expected gradual haemoconcentration. Fifth, due to missing data, effects on bleeding complications induced by potential premedications (e.g. with oral anticoagulants) cannot be ruled out in our analysis. Sixth, it seems important to note that estimated, rather than exact (i.e. measured) lost blood volumes were assessed. However, this may imply a systematic error and may be of minor importance.
Conclusions
Clinically significant episodes of bleeding with respective transfusion requirements may often be observed in critically ill patients with dialysis-dependent ARF on RRT. Our data show that the underlying condition, rather than the chosen RRT modality (i.e. IHD versus CVVH) is associated with the rate of bleeding complications. Overall, our data add to mounting data indicating that IHD and CVVH may be considered equivalent approaches in critically ill patients with dialysis-dependent ARF.
